You are here: Industry Insights > immunotherapy

News List

Harnessing immunotherapy to reverse Type 1 diabetes fiercebiotech
November 16, 2017
In patients with Type 1 diabetes, T cells in the immune system mistakenly attack islet cells in the pancreas that make insulin
Allergy Therapeutics kicks off dosing in grass immunotherapy trial pharmatimes
October 20, 2017
Allergy Therapeutics has begun dosing in a mid-stage trial designed to assess the dose-response and safety of its ultra-short course PQ Grass immunotherapy, which targets the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
Bavarian Nordic hit by cancer immunotherapy failure pharmatimes
September 19, 2017
Bavarian Nordic saw its shares plummet as much as 50 percent in the wake of news that the firm’s cancer immunotherapy ProstVac failed to prolong survival in men with a particular type of prostate cancer.
Immunotherapy combination safe and 62 percent effective in metastatic melanoma patients worldpharmanews
September 08, 2017
Immunotherapy is a promising approach in the treatment of metastatic melanoma, an aggressive and deadly form of skin cancer; but for most patients, immunotherapy drugs so far have failed to live up to their promise and provide little or no benefit.
Researchers discover new immunotherapy combination effective at killing cancer cells worldpharmanews
August 31, 2017
Doug Mahoney's lab at the University of Calgary recently discovered an immunotherapy that uses existing cancer drugs in a whole new way.
Immunotherapy combination effective at killing cancer cells europeanpharmaceuticalreview
August 31, 2017
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way…
SillaJen and NCI partner to develop new colorectal cancer treatment pharmaceutical-technology
August 21, 2017
Korean-based SillaJen has entered a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), US, to develop a new combination therapy for colorectal cancer (CRC).
Independent research may change the immunotherapy game pharmafile
August 18, 2017
Treatments are so successful, in certain patients, that they’ve become an extremely lucrative market – so much so that AstraZeneca’s fortunate were sunk on the poor result of one combination trial with its own PD-L1 inhibitor, Imfinzi.
The hottest PK between PD-1/PD-L1 antibodies immunotherapy en-cphi.cn
August 11, 2017
The immunotherapy is undoubtedly the hot field that has attracted the most attention of the industry in recent years.
The hottest PK between PD-1/PD-L1 antibodies immunotherapy en-cphi.cn
August 11, 2017
The immunotherapy is undoubtedly the hot field that has attracted the most attention of the industry in recent years.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page